Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle®)
product platform, today announced it has been awarded a contract from
the Department of Health and Social Care as part of the Small Business
Research Initiative, or SBRI. SBRI Healthcare is an initiative to
identify new ideas and technologies addressing future challenges to the
U.K.’s National Health Service (NHS). Under the contract, Bicycle will
identify Bicycle® inhibitors to a range of Penicillin
Binding Proteins (PBPs) from pathogens of significant medical concern
and investigate their antimicrobial activity.

Bicycle’s research proposal was submitted in response to a competitive
call for novel strategies targeting antimicrobial resistance in humans.
Since 2009, Bicycle Therapeutics has addressed more than 90 drug targets
with an 80 percent success rate, leading to two ongoing clinical
programs, including its lead program BT1718 which is in Phase I/IIa for
oncology. Under this new award, Bicycle will now adapt its ultra-high
throughput proprietary phage screening platforms to screen targets to
discover novel inhibitors of PBPs, key drug targets that catalyze
bacterial cell wall biosynthesis. Bicycle will target the PBPs of key
bacterial pathogens classified by the World Health Organization as
either “critical” or “high” threats and which present a significant
healthcare concern for U.K. hospitals. The work will be led by Dr. Mike
Dawson, an industry veteran with more than 30 years of experience in
infectious disease drug discovery and development.

“Bicycle’s unique and versatile technology is well-suited to creating a
new class of antibacterial agents to address widespread antibiotic
resistance, and we are honored to receive this funding from SBRI
Healthcare,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle
Therapeutics. “The Department of Health and Social Care’s recent
announcement of a five-year plan to target antimicrobial resistance,
along with its commitment to trial reimbursement mechanisms that are
decoupled from antibiotic sales, marks a sea change in incentives for
companies like ours with the technology to address antibiotic
resistance. Patients worldwide will benefit from a more robust market
for antimicrobials.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a unique class of chemically
synthesised medicines based on its proprietary bicyclic peptide (Bicycle®)
product platform to address therapeutic needs unreachable with existing
treatment modalities. Bicycle’s internal focus is in oncology, where the
company is developing targeted cytotoxics (Bicycle Toxin Conjugates®),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and
highly selective targeting deliver rapid tumour penetration and
retention while clearance rates and routes of elimination can be tuned
to minimise exposure of healthy tissue and bystander toxicities. The
company’s lead program, BT1718, is being evaluated in a Phase I/IIa
trial in collaboration with Cancer Research UK. The company’s unique
intellectual property is based on the work initiated at the MRC
Laboratory of Molecular Biology in Cambridge, U.K., by the scientific
founders of the company, Sir Greg Winter, a winner of the Nobel Prize in
Chemistry for his pioneering work in phage display of
peptides and antibodies, and Professor Christian Heinis. Bicycle has its
headquarters in Cambridge, U.K., with many key functions and members of
its leadership team located in the biotech hub of Boston, Mass. For more
information, visit or
follow us on Twitter at @Bicycle_tx.


Ten Bridge Communications
Sara Green
[email protected]

Maeve Conneighton
[email protected]

error: Content is protected !!